PDF(Pubmed)
Abstract：
UNASSIGNED: This investigation evaluated the prognostic significance of the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), and introduced a combined NLR-PLR score to evaluate the correlation between NLR-PLR score and hepatocellular carcinoma (HCC) recurrence.
UNASSIGNED: We enrolled 110 patients who underwent orthotopic liver transplantation (LT) for HCC. The neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were assessed, and appropriate cut-off values were established. The NLR-PLR score ranged from 0 to 2 as follows: score of 2, high NLR (≥3.37) and high PLR (≥105.96); score of 1, either high NLR or high PLR; score of 0, neither high NLR nor high PLR.
UNASSIGNED: The median overall survival (OS) of patients with NLR-PLR score of 0, 1 and 2 was 27, 26.5, and 6 months, respectively. The median OS of patients with NLR-PLR score of 2 was shorter than those with 0 (P < 0.001) and 1 (P < 0.001). The median disease-free survival (DFS) time of patients with NLR-PLR score of 0, 1 and 2 was 24.5, 24, and 6 months, The median DFS of patients with NLR-PLR score of 2 was shorter than those with 0 (P = 0.001) and 1 (P = 0.015). Multivariate analysis showed that NLR-PLR score was an independent risk factor for prognosis and survival.
UNASSIGNED: NLR, PLR and NLR-PLR score can predict the long-term survival of patients, and NLR-PLR score, having more predictive value than NLR and PLR alone is an independent risk factor for patient survival. more predictive value than NLR and PLR alone.
UNASSIGNED: We enrolled 110 patients who underwent orthotopic liver transplantation (LT) for HCC. The neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were assessed, and appropriate cut-off values were established. The NLR-PLR score ranged from 0 to 2 as follows: score of 2, high NLR (≥3.37) and high PLR (≥105.96); score of 1, either high NLR or high PLR; score of 0, neither high NLR nor high PLR.
UNASSIGNED: The median overall survival (OS) of patients with NLR-PLR score of 0, 1 and 2 was 27, 26.5, and 6 months, respectively. The median OS of patients with NLR-PLR score of 2 was shorter than those with 0 (P < 0.001) and 1 (P < 0.001). The median disease-free survival (DFS) time of patients with NLR-PLR score of 0, 1 and 2 was 24.5, 24, and 6 months, The median DFS of patients with NLR-PLR score of 2 was shorter than those with 0 (P = 0.001) and 1 (P = 0.015). Multivariate analysis showed that NLR-PLR score was an independent risk factor for prognosis and survival.
UNASSIGNED: NLR, PLR and NLR-PLR score can predict the long-term survival of patients, and NLR-PLR score, having more predictive value than NLR and PLR alone is an independent risk factor for patient survival. more predictive value than NLR and PLR alone.
摘要：
■这项研究评估了中性粒细胞-淋巴细胞比率（NLR）和血小板-淋巴细胞比率（PLR）的预后意义，并介绍了联合NLR-PLR评分来评估NLR-PLR评分与肝细胞癌（HCC）复发之间的相关性。
■我们招募了110例接受原位肝移植（LT）治疗肝癌的患者。评估中性粒细胞-淋巴细胞比率（NLR）和血小板-淋巴细胞比率（PLR），并建立了适当的临界值。NLR-PLR评分从0到2分，如下：2分，高NLR（≥3.37）和高PLR（≥105.96）；1分，高NLR或高PLR；0分，既不高NLR也不高PLR。
■NLR-PLR评分为0、1和2的患者的中位总生存期（OS）为27、26.5和6个月，分别。NLR-PLR评分为2分的患者的中位OS短于0分(P<0.001)和1分(P<0.001)。NLR-PLR评分分别为0、1和2分的患者的中位无病生存期(DFS)时间分别为24.5、24和6个月,NLR-PLR评分为2分的患者的中位DFS短于0分(P=0.001)和1分(P=0.015)。多因素分析显示NLR-PLR评分是影响预后和生存的独立危险因素。
■NLR，PLR和NLR-PLR评分可以预测患者的长期生存率,和NLR-PLR得分，比单独使用NLR和PLR更具预测价值是患者生存的独立危险因素.比单独的NLR和PLR更具预测价值。
■我们招募了110例接受原位肝移植（LT）治疗肝癌的患者。评估中性粒细胞-淋巴细胞比率（NLR）和血小板-淋巴细胞比率（PLR），并建立了适当的临界值。NLR-PLR评分从0到2分，如下：2分，高NLR（≥3.37）和高PLR（≥105.96）；1分，高NLR或高PLR；0分，既不高NLR也不高PLR。
■NLR-PLR评分为0、1和2的患者的中位总生存期（OS）为27、26.5和6个月，分别。NLR-PLR评分为2分的患者的中位OS短于0分(P<0.001)和1分(P<0.001)。NLR-PLR评分分别为0、1和2分的患者的中位无病生存期(DFS)时间分别为24.5、24和6个月,NLR-PLR评分为2分的患者的中位DFS短于0分(P=0.001)和1分(P=0.015)。多因素分析显示NLR-PLR评分是影响预后和生存的独立危险因素。
■NLR，PLR和NLR-PLR评分可以预测患者的长期生存率,和NLR-PLR得分，比单独使用NLR和PLR更具预测价值是患者生存的独立危险因素.比单独的NLR和PLR更具预测价值。
